290 related articles for article (PubMed ID: 34272731)
21. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
Liu F; Tian S; Liu Q; Deng Y; He Q; Shi Q; Chen G; Xu X; Yuan J; Nakamura S; Karube K; Wang Z
Cancer Med; 2024 Feb; 13(4):e6995. PubMed ID: 38457199
[TBL] [Abstract][Full Text] [Related]
22. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?
Ok CY; Ye Q; Li L; Manyam GC; Deng L; Goswami RR; Wang X; Montes-Moreno S; Visco C; Tzankov A; Dybkaer K; Zhang L; Abramson J; Sohani AR; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhang S; Parsons BM; Xu M; Møller MB; Winter JN; Piris MA; Xu-Monette ZY; Medeiros LJ; Young KH
Oncotarget; 2015 Jun; 6(16):13933-45. PubMed ID: 26101854
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome.
Gorodetskiy VR; Probatova NA; Vasilyev VI
Int J Rheum Dis; 2020 Apr; 23(4):540-548. PubMed ID: 32100426
[TBL] [Abstract][Full Text] [Related]
25. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
Ramis-Zaldivar JE; Gonzalez-Farre B; Nicolae A; Pack S; Clot G; Nadeu F; Mottok A; Horn H; Song JY; Fu K; Wright G; Gascoyne RD; Chan WC; Scott DW; Feldman AL; Valera A; Enjuanes A; Braziel RM; Smeland EB; Staudt LM; Rosenwald A; Rimsza LM; Ott G; Jaffe ES; Salaverria I; Campo E
Haematologica; 2021 Oct; 106(10):2682-2693. PubMed ID: 33951889
[TBL] [Abstract][Full Text] [Related]
26. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
[TBL] [Abstract][Full Text] [Related]
28.
Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
[TBL] [Abstract][Full Text] [Related]
29. Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern.
Delecluse HJ; Hummel M; Marafioti T; Anagnostopoulos I; Stein H
J Pathol; 1999 Jun; 188(2):133-8. PubMed ID: 10398155
[TBL] [Abstract][Full Text] [Related]
30. Mutational landscape of gray zone lymphoma.
Sarkozy C; Hung SS; Chavez EA; Duns G; Takata K; Chong LC; Aoki T; Jiang A; Miyata-Takata T; Telenius A; Slack GW; Molina TJ; Ben-Neriah S; Farinha P; Dartigues P; Damotte D; Mottok A; Salles GA; Casasnovas RO; Savage KJ; Laurent C; Scott DW; Traverse-Glehen A; Steidl C
Blood; 2021 Apr; 137(13):1765-1776. PubMed ID: 32961552
[TBL] [Abstract][Full Text] [Related]
31. Frequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Noujima-Harada M; Takata K; Miyata-Takata T; Sakurai H; Igarashi K; Ito E; Nagakita K; Taniguchi K; Ohnishi N; Omote S; Tabata T; Sato Y; Yoshino T
Cancer Sci; 2017 May; 108(5):1071-1079. PubMed ID: 28256087
[TBL] [Abstract][Full Text] [Related]
32. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.
Courville EL; Yohe S; Chou D; Nardi V; Lazaryan A; Thakral B; Nelson AC; Ferry JA; Sohani AR
Mod Pathol; 2016 Oct; 29(10):1200-11. PubMed ID: 27443517
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
Ok CY; Li L; Xu-Monette ZY; Visco C; Tzankov A; Manyam GC; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Chen J; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ai W; Ponzoni M; Ferreri AJ; Farnen JP; Møller MB; Bueso-Ramos CE; Miranda RN; Winter JN; Piris MA; Medeiros LJ; Young KH
Clin Cancer Res; 2014 May; 20(9):2338-49. PubMed ID: 24583797
[TBL] [Abstract][Full Text] [Related]
34. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
35. Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.
Wawire J; Sayed S; Moloo Z; Sohani AR
J Glob Oncol; 2019 May; 5():1-8. PubMed ID: 31045473
[TBL] [Abstract][Full Text] [Related]
36. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
Richter J; John K; Staiger AM; Rosenwald A; Kurz K; Michgehl U; Ott G; Franzenburg S; Kohler C; Finger J; Oschlies I; Paul U; Siebert R; Spang R; Burkhardt B; Klapper W
Br J Haematol; 2022 Feb; 196(3):681-689. PubMed ID: 34617271
[TBL] [Abstract][Full Text] [Related]
38. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
[TBL] [Abstract][Full Text] [Related]
39. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
40. The presence of Epstein-Barr virus (EBV) in diffuse large B-cell lymphomas (DLBCLs) in Turkey: special emphasis on 'EBV-positive DLBCL of the elderly'.
Uner A; Akyurek N; Saglam A; Abdullazade S; Uzum N; Onder S; Barista I; Benekli M
APMIS; 2011 Apr; 119(4-5):309-16. PubMed ID: 21492232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
